CHO cell line specific prediction and control of recombinant monoclonal antibody n-glycosylation

Biotechnology and Bioengineering

Volumn 110, Issue 11, 2013, Pages 2970-2983

  Grainger, Rhian K ^a   James, David C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Chinese hamster ovary cells; Design of experiments; Monoclonal antibodies; N glycosylation

Indexed keywords

CHINESE HAMSTER OVARY CELLS; COMPARATIVE MEASUREMENTS; MANUFACTURING PROCESS; MOLECULAR HETEROGENEITY; N-GLYCOSYLATION; PREDICTION AND CONTROL; RECOMBINANT MONOCLONAL ANTIBODY; SYNERGISTIC COMBINATIONS;

CELL CULTURE; CELL GROWTH; CELL MEMBRANES; DESIGN OF EXPERIMENTS; ESTERIFICATION; FLUORESCENCE; FORECASTING; GLYCOSYLATION; GROWTH KINETICS; MANGANESE; POLYSACCHARIDES; PROTEINS; REAL TIME CONTROL;

MONOCLONAL ANTIBODIES;

GALACTOSE; GLYCAN; LECTIN; MANGANESE; MONOCLONAL ANTIBODY; URIDINE;

ACCURACY; ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CHO CELL; CONTROLLED STUDY; FEEDBACK SYSTEM; GLYCOSYLATION; NONHUMAN; PROCESS DEVELOPMENT;

CRICETULUS GRISEUS;

CHINESE HAMSTER OVARY CELLS; DESIGN OF EXPERIMENTS; MONOCLONAL ANTIBODIES; N-GLYCOSYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BETA-GLUCANS; CHO CELLS; CRICETULUS; FLOW CYTOMETRY; GLYCOSYLATION; IMMUNOGLOBULIN G; LECTINS; MEMBRANE PROTEINS; MODELS, STATISTICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS;

EID: 84884530112     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24959     Document Type: Article

References (68)

1. Altamirano C, Paredes C, Cairo JJ, Godia F. 2000. Improvement of CHO cell culture medium formulation: simultaneous substitution of glucose and glutamine. Biotechnol Prog 16(1):69-75.
2. Altamirano C, Cairo JJ, Godia F. 2001. Decoupling cell growth and product formation in Chinese hamster ovary cells through metabolic control. Biotechnol Bioeng 76(4):351-360.
3. Altamirano C, Paredes C, Illanes A, Cairo JJ, Godia F. 2004. Strategies for fed-batch cultivation of t-PA producing CHO cells: Substitution of glucose and glutamine and rational design of culture medium. J Biotechnol 110:171-179.
4. Altamirano C, Illanes A, Becerra S, Cairo JJ, Godia F. 2006. Considerations on the lactate consumption by CHO cells in the presence of galactose. J Biotechnol 125:547-556.
5. Amanullah A, Otero JM, Mikola M, Hsu A, Zhang J, Aunins J, Schreyer HB, Hope JA, Russo AP. 2010. Novel micro-bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed-batch CHO cultures. Biotechnol Bioeng 106(1):57-67.
6. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21-50.
7. Baker KN, Rendall MH, Hills AE, Hoare M, Freedman RB, James DC. 2001. Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol Bioeng 73:188-202.
8. Beck A, Sanglier-Cianferani S, Van Dorsselaer A. 2012. Biosimilar, biobetter, and next generation antibody characterisation by mass spectrometry. Anal Chem 84(11):4637-4646.
9. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. 2012. Analytical tools for characterising biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 11(7):527-540.
10. Boeggeman E, Qasba PK. 2002. Studies on the metal binding sites in the catalytic domain of beta1, 4-galactosyltransferase. Glycobiology 12:395-407.
11. Burleigh SC, van de Laar T, Stroop CJM, van Grunsven WMJ, O'Donoghue N, Rudd PM, Davey GP. 2011. Synergizing metabolic flux analysis and nucleotide sugar metabolism to understand the control of glycosylation of recombinant protein in CHO cells. BMC Biotechnol 11(1):95-112.
12. Cecchelli R, Cacan R, Verbert A. 1986. Mechanism of UDP-sugar transport into intracellular vesicles. Occurrence of UDP-GlcNAc/UDP and UDP-Gal/UDP antiports. FEBS Lett 208:407-412.
13. Chen PF, Harcum SW. 2006. Effects of elevated ammonium on glycosylation gene expression in CHO cells. Metab Eng 8:123-132.
14. Crowell CK, Grampp GE, Rogers GN, Miller J, Scheinman RI. 2007. Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol Bioeng 96:538-549.
15. Davies SL, Lovelady CS, Grainger RK, Racher AJ, Young RJ, James DC. 2012. Functional heterogeneity in CHO cell populations. Biotechnol Bioeng 110(1):260-274.
16. Deutscher SL, Hirschberg CB. 1986. Mechanism of galactosylation in the Golgi apparatus. A Chinese hamster ovary cell mutant deficient in translocation of UDP-galactose across Golgi vesicle membranes. J Biol Chem 261:96-100.
17. Deutscher SL, Nuwayhid N, Stanley P, Briles EI, Hirschberg CB. 1984. Translocation across Golgi vesicle membranes: A CHO glycosylation mutant deficient in CMP-sialic acid transport. Cell 39:295-299.
18. Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ET, Gerritsen J, van Berkel PH. 2011. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 108:1591-1602.
19. Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA. 1996. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 240(2):210-226.
20. Gupta D, Oscarson S, Raju TS, Stanley P, Toone EJ, Brewer CF. 1996. A comparison of the fine saccharide-binding specificity of Dioclea grandiflora lectin and concanavalin A. Eur J Biochem 242(2):320-326.
21. Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, Bobrowicz P, Stadheim TA, Li H, Choi BK, Hopkins D, Wischnewski H, Roser J, Mitchell T, Strawbridge RR, Hoopes J, Wildt S, Gerngross TU. 2006. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313:1441-1443.
22. Hills AE, Patel A, Boyd P, James DC. 2001. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol Bioeng 75:239-251.
23. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21:1644-1652.
24. Hossler P, Mulujutla BC, Hu WS. 2007. Systems analysis of N-glycan processing in mammalian cells. PLoS ONE 2(1):e713.
25. Huang Y-M, Hu W-W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T. 2010. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol Prog 26(5):1400-1410.
26. Jefferis R. 2009. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30:356-362.
27. Jiang HT, Wu SL, Karger BL, Hancock WS. 2011. Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal Chem 82(14):6154-6162.
28. Jimenez del Val I, Nagy JM, Kontoravdi C. 2011. A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus. Biotechnol Prog 27(6):1730-1743.
29. Jing Y, Qian Y, Li ZJ. 2010. Sialylation enhancement of CTLA4-Ig fusion protein in Chinese hamster ovary cells by dexamethasone. Biotechnol Bioeng 107(3):488-496.
30. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX. 2010. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70:4481-4489.
31. Klohs WD, Wilson JR, Weiser MM, Frankfurt O, Bernacki RJ. 1984. Galactosyltransferase activity and cell growth: Uridine diphosphate (UDP)galactose inhibition of murine leukemic L1210 cells. J Cell Physiol 119:23-28.
32. Kornfeld R, Kornfeld S. 1985. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54:631-664.
33. Legmann R, Schreyer HB, Combs RG, McCormick EL, Russo AP, Rodgers ST. 2009. A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnol Bioeng 104(6):1107-1120.
34. Li Y, Tao S-C, Zhu H, Schneck JP. 2011. High-throughput lectin microarray-based analysis of live cell surface glycosylation. Curr Protoc Protein Sci 63:12.9.1-12.9.7.
35. Majid FA, Butler M, Al-Rubeai M. 2007. Glycosylation of an immunoglobulin produced from a murine hybridoma cell line: The effect of culture mode and the anti-apoptotic gene, bcl-2. Biotechnol Bioeng 97:156-169.
36. Mandal DK, Brewer CF. 1993. Differences in the binding affinities of dimeric concanavalin A (including acetyl and succinyl derivatives) and tetrameric concanavalin A with large oligomannose-type glycopeptides. Biochemistry 32(19):5116-5120.
37. Mandenius CF, Brundin A. 2008. Bioprocess optimization using design-of-experiments methodology. Biotechnol Progress 24:1191-1203.
38. Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter-Katalinic J. 2003. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng 83:321-334.
39. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133.
40. Pacis E, Yu M, Autsen J, Bayer R, Li F. 2011. Effects of cell culture conditions on antibody N-linked glycosylation-What affects high mannose 5 glycoform. Biotechnol Bioeng 108:2348-2358.
41. Patnaik SK, Stanley P. 2006. Lectin-resistant CHO glycosylation mutants. Methods Enzymol 416:159-182.
42. Pels Rijcken WR, Overdijk B, Van den Eijnden DH, Ferwerda W. 1995. The effect of increasing nucleotide-sugar concentrations on the incorporation of sugars into glycoconjugates in rat hepatocytes. Biochem J 305:865-870.
43. Penno MB, Passaniti A, Fridman R, Hart GW, Jordan C, Kumar S, Scott AF. 1989. In vitro galactosylation of a 110-kDa glycoprotein by an endogenous cell surface galactosyltransferase correlates with the invasiveness of adrenal carcinoma cells. Proc Natl Acad Sci USA 86(16):6057-6061.
44. Porwoll S, Loch N, Kannicht C, Nuck R, Grunow D, Reutter W, Tauber R. 1998. Cell surface glycoproteins undergo postbiosynthetic modification of their N-glycans by stepwise demannosylation. J Biol Chem 273:1075-1085.
45. Ramakrishnan B, Boeggeman E, Ramasamy V, Qasba PK. 2004. Structure and catalytic cycle of beta-1, 4-galactosyltransferase. Curr Opin Struct Biol 14:593-600.
46. Ripka J, Stanley P. 1986. Lectin-resistant CHO cells: Selection of four new pea lectin-resistant phenotypes. Somat Cell Mol Genet 12:51-62.
47. Ripka J, Adamany A, Stanley P. 1986. Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. Arch Biochem Biophys 249:533-545.
48. Ryll T, Wagner R. 1992. Intracellular ribonucleotide pools as a tool for monitoring the physiological state of in vitro cultivated mammalian cells during production processes. Biotechnol Bioeng 40:934-946.
49. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. 2011. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29(4):310-312.
50. Schoenherr I, Stapp T, Ryll T. 2000. A comparison of different methods to determine the end of exponential growth in CHO cell cultures for optimization of scale-up. Biotechnol Prog 16:815-821.
51. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740.
52. Silk NJ, Denby S, Lewis G, Kuiper M, Hatton D, Field R, Baganz F, Lye GJ. 2010. Fed-batch operation of an industrial cell culture process in shaken microwells. Biotechnol Lett 32(1):73-78.
53. Sokoloski JA, Lee CW, Handschumacher RE, Nigam A, Sartorelli AC. 1991. Effects of uridine on the growth and differentiation of HL-60 leukemia cells. Leuk Res 15:1051-1058.
54. Stanley P. 1981. Selection of specific wheat germ agglutinin-resistant (WgaR) phenotypes from Chinese hamster ovary cell populations containing numerous lecR genotypes. Mol Cell Biol 1:687-696.
55. Stanley P, Siminovitch L. 1977. Complementation between mutants of CHO cells resistant to a variety of plant lectins. Somatic Cell Genet 3:391-405.
56. Stanley P, Caillibot V, Siminovitch L. 1975a. Selection and characterization of eight phenotypically distinct lines of lectin-resistant Chinese hamster ovary cell. Cell 6:121-128.
57. Stanley P, Narasimhan S, Siminovitch L, Schachter H. 1975b. Chinese hamster ovary cells selected for resistance to the cytotoxicity of phytohemagglutinin are deficient in a UDP-N-acetylglucosamine-glycoprotein N-acetylglucosaminyltransferase activity. Proc Natl Acad Sci USA 72:3323-3327.
58. Takagi M, Hayashi H, Yoshida T. 2000. The effect of osmolarity on metabolism and morphology in adhesion and suspension Chinese hamster ovary cells producing tissue plasminogen activator. Cytotechnology 32(3):171-179.
59. Tao SC, Li Y, Zhou J, Qian J, Schnaar RL, Zhang Y, Goldstein IJ, Zhu H, Schneck JP. 2008. Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers. Glycobiology 18(10):761-769.
60. Tateno H, Uchiyama N, Kuno A, Togayachi A, Sato T, Narimatsu H, Hirabayashi J. 2007. A novel strategy for mammalian cell surface glycome profiling using lectin microarray. Glycobiology 17:1138-1146.
61. Umana P, Ekkehard M, Peter B, Gabriele K, Ursula P, Suter T, Grau R, Schmidt C, Herter S, Gerdes C, Nopora A, Patre M, Moser S, Sondermann P, Wheat L, Dyer MJS, Poppema S, Bauer S, Kubbies M, Strein P, Fertig G, Friess T, Dabbagh K, DalPorto J, Klein C. 2007. GA101, a novel humanized type II CD20 Antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood 110(11):694a.
62. van Berkel PHC, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JGJ, Parren PWHI. 2009. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol Prog 25:244-251.
63. Wang C, He XH, Zhou B, Li J, Li BH, Qian WZ, Hou S, Wang H, Shi YK, Guo YJ. 2011. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs 3(1):67-75.
64. Warnock D, Bai X, Autote K, Gonzales J, Kinealy K, Yan B, Qian J, Stevenson T, Zopf D, Bayer RJ. 2005. In vitro galactosylation of human IgG at 1kg scale using recombinant galactosyltransferase. Biotechnol Bioeng 92(7):831-842.
65. Wong NS, Wati L, Nissom PM, Ht F, Mm L, Yap MG. 2010. An investigation of intracellular glycosylation activities in CHO cells: Effects of nucleotide sugar precursor feeding. Biotechnol Bioeng 107(2):321-336.
66. Wu JH, Herp A, Wu AM. 1993. Defining carbohydrate specificity of Ricinus communis agglutinin as Gal beta 1→4GlcNAc (II)>Gal beta 1→3GlcNAc (I)>Gal alpha 1→3Gal (B)>Gal beta 1→3GalNAc (T). Mol Immunol 30(4):333-339.
67. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, Chen W, Skilton SJ, Mazzeo JR. 2010. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2(4):379-394.
68. Zhong J-J, Zhang P, Chan KF, Haryadi R, Bardor M, Song Z. 2012. CHO glycosylation mutants as potential host cells to produce therapeutic proteins with enhanced efficacy. Future Trends in Biotechnology. J-J Zhong, Springer Berlin Heidelberg 63-87.